Contact an Expert

Detect Viral Contamination

Merck:/Freestyle/PS-Process-Solutions/Learning-Centers/Virus-Safety-Assurance/detect-lab-image.jpgGlobal regulatory guidance documents and reflection papers outline biosafety testing strategies and recommendations for viral testing; their expectation is that no adventitious virus should be detected in production processes. Traditional tests for adventitious viruses offer opportunities for broad detection of diverse viruses however, these are time consuming tests and have limitations in terms of sensitivity and identification of specific contaminants.

Molecular testing technologies such as Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS) complement traditional cell based methods, opening doors for more rapid, sensitive detection of viral contaminants.

Browse this page and learn more on viral detection challenges and innovation.

Watch our video to learn more about viral detection
1. Confirm that adventitious agents are not present in cell banks
Cell line characterization is required by the regulatory bodies to confirm the species origin and history of the cell line; and characterize and test its identity, stability, and purity.

Featured Solution


This webinar describes a number of topics in the areas of cell line characterization and bulk harvest testing for contaminants where new technical innovations are occurring. The regulatory response to these developments is discussed.

More Resources

Merck:/Freestyle/PS-Process-Solutions/Learning-Centers/Virus-Safety-Assurance/icon-note-rp.svg Article: GEN roundup on cell-line authentication
Merck:/Freestyle/PS-Process-Solutions/Learning-Centers/Virus-Safety-Assurance/icon-note-rp.svg Viral risk mitigation: A global regulatory perspective – Special report, BPI, 2018

Product Information
Cell line characterization

Cell Line Characterization is required by the regulatory bodies to confirm the species origin and history of the cell line; and characterize and test the identity, stability and purity.

2. Confirm that adventitious agents are not present in raw materials and bulks
Variability is inherently introduced by bioprocessing raw materials. A detailed initiative to fully characterize raw materials using orthogonal techniques can provide assurance that the raw materials are fit for purpose.

Featured Solution


In this webinar you will learn:
  • Approaches to develop a risk mitigation program
  • Methods of characterizing biopharma raw materials
  • Variability in biopharma raw materials

More Resources

Merck:/Freestyle/PS-Process-Solutions/Learning-Centers/Virus-Safety-Assurance/icon-note-rp.svg Article: Clearing viral concerns in animal-derived biomaterials

Merck:/Freestyle/PS-Process-Solutions/Learning-Centers/Virus-Safety-Assurance/icon-note-rp.svg Article: Assuring equivalency of alternative lot-release test methods

Product Information
Raw material testing

Our services are aimed at ensuring the quality and purity of raw materials used in the production of biologics

Bulk lot release testing

We offer a comprehensive range of services and assays aimed at ensuring the quality and purity of unprocessed and purified bulk harvest materials used in the production of biologicals for the pharmaceutical and biotech industries.

3. Accelerate biosafety testing of biological therapies
Increased understanding of viral contamination risks in biologics production, and the need for manufacturers to have rapid results, has necessitated development of fast, sensitive tests for detecting viral contamination.  

Featured Solution


This webinar explores how rapid methodologies are being used to accelerate biosafety testing and enhance quality by reducing testing complexity. Existing technologies as well as emerging trends are discussed, along with the implications these may have on the regulatory landscape.

More Resources

Merck:/Freestyle/PS-Process-Solutions/Learning-Centers/Virus-Safety-Assurance/icon-note-rp.svg Sponsored tutorial, GEN: Utility of Next-Generation Sequencing (NGS) for Biosafety Assessment of Biological Products

Product Information
Next Generation Sequencing

Our expertise in NGS-based biosafety testing services allows us to provide complete genomic analysis solutions to our clients, from sample preparation and library generation through sequencing and data mining using state of the art computational and bioinformatics platforms, tools and methodologies.

4. Detect emerging viruses in raw materials
Viral contamination is a constant challenge to all biopharmaceutical production processes. Emerging viruses are of particular concern and need to be characterized to understand the potential threat to your process. Understanding the susceptibility of your raw materials to these viral contaminants, and the capability of classical assays to detect them, will affect your viral safety strategy.  

Featured Solution


Using Zika, Schmallenberg and Hepatitis E viruses as examples, watch our webinar to learn how to evaluate the risk of emerging viruses in raw materials and integrate appropriate testing into a holistic viral safety strategy.

More Resources

Merck:/Freestyle/PS-Process-Solutions/Learning-Centers/Virus-Safety-Assurance/icon-note-rp.svg Article: Schmallenberg virus, an emerging viral pathogen of cattle and sheep and a potential contaminant of raw materials, is detectable by classical in-vitro adventitious virus assays

Merck:/Freestyle/PS-Process-Solutions/Learning-Centers/Virus-Safety-Assurance/icon-note-rp.svg Article: Mitigating the risk of Zika virus contamination of raw materials and cell lines in the manufacture of biologicals

Product Information

Adventitious Agents / Virology Testing

We perform in vitro assays designed to detect adventitious viruses in cell banks, virus seed stock, raw materials and final products.